Vera Therapeutics (NASDAQ:VERA) Trading Up 10.2% – What’s Next?

Vera Therapeutics, Inc. (NASDAQ:VERA) traded up 10.2% during mid-day trading on Tuesday . The stock traded as high as $45.38 and last traded at $42.9290. 936,065 shares were traded during mid-day trading, a decline of 12% from the average session volume of 1,069,727 shares. The stock had previously closed at $38.97.

Analyst Upgrades and Downgrades

VERA has been the topic of a number of recent analyst reports. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Evercore raised their target price on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Wedbush raised their price objective on Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Pivotal Research set a $73.00 target price on Vera Therapeutics in a report on Friday, December 5th. Finally, Bank of America upped their price objective on shares of Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $80.80.

Vera Therapeutics Price Performance

The stock has a market capitalization of $2.94 billion, a PE ratio of -9.03 and a beta of 1.17. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12. The stock’s 50-day moving average is $44.56 and its 200 day moving average is $36.43.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same period in the prior year, the firm posted ($0.72) EPS. As a group, equities analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CFO Sean Grant sold 4,949 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $207,759.02. Following the completion of the sale, the chief financial officer directly owned 114,181 shares in the company, valued at $4,793,318.38. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO David Lee Johnson sold 2,579 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $108,266.42. Following the sale, the chief operating officer owned 45,727 shares of the company’s stock, valued at approximately $1,919,619.46. The trade was a 5.34% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 33,490 shares of company stock worth $1,405,910. 16.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after acquiring an additional 236 shares during the period. Los Angeles Capital Management LLC bought a new stake in Vera Therapeutics in the fourth quarter valued at about $46,000. Quantbot Technologies LP acquired a new position in Vera Therapeutics in the second quarter worth about $51,000. Aster Capital Management DIFC Ltd bought a new position in Vera Therapeutics during the fourth quarter worth about $71,000. Finally, Virtus Investment Advisers LLC lifted its stake in Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after purchasing an additional 539 shares during the period. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.